no code implementations • 26 Oct 2023 • Reinhard Laubenbacher, Fred Adler, Gary An, Filippo Castiglione, Stephen Eubank, Luis L. Fonseca, James Glazier, Tomas Helikar, Marti Jett-Tilton, Denise Kirschner, Paul Macklin, Borna Mehrad, Beth Moore, Virginia Pasour, Ilya Shmulevich, Amber Smith, Isabel Voigt, Thomas E. Yankeelov, Tjalf Ziemssen
If medical digital twins are to faithfully capture the characteristics of a patient's immune system, we need to answer many questions, such as: What do we need to know about the immune system to build mathematical models that reflect features of an individual?
no code implementations • 29 Sep 2023 • Guillermo Lorenzo, Jon S. Heiselman, Michael A. Liss, Michael I. Miga, Hector Gomez, Thomas E. Yankeelov, Alessandro Reali, Thomas J. R. Hughes
We further show that coupling our tumor forecasts with this PCa risk classifier enables the early identification of PCa progression to higher-risk disease by more than one year.
no code implementations • 28 Aug 2023 • Guillermo Lorenzo, Syed Rakin Ahmed, David A. Hormuth II, Brenna Vaughn, Jayashree Kalpathy-Cramer, Luis Solorio, Thomas E. Yankeelov, Hector Gomez
Despite the remarkable advances in cancer diagnosis, treatment, and management that have occurred over the past decade, malignant tumors remain a major public health problem.
no code implementations • 8 Dec 2022 • Guillermo Lorenzo, Angela M. Jarrett, Christian T. Meyer, Vito Quaranta, Darren R. Tyson, Thomas E. Yankeelov
As longitudinal \textsl{in vivo} MRI data for model calibration is limited, we perform a sensitivity analysis to identify the model mechanisms driving the response to two NAC drug combinations: doxorubicin with cyclophosphamide, and paclitaxel with carboplatin.
no code implementations • 3 May 2022 • Kalina P. Slavkova, Julie C. DiCarlo, Viraj Wadhwa, Chengyue Wu, John Virostko, Sidharth Kumar, Thomas E. Yankeelov, Jonathan I. Tamir
We conclude that the use of an untrained neural network together with a physics-based regularization loss shows promise as a measure for determining the optimal stopping point in training without relying on fully-sampled ground truth data.
no code implementations • 24 Feb 2021 • Guillermo Lorenzo, David A. Hormuth II, Angela M. Jarrett, Ernesto A. B. F. Lima, Shashank Subramanian, George Biros, J. Tinsley Oden, Thomas J. R. Hughes, Thomas E. Yankeelov
Current clinical decision-making in oncology relies on averages of large patient populations to both assess tumor status and treatment outcomes.
no code implementations • 17 Sep 2018 • Manasa Gadde, Caleb Phillips, Neda Ghousifam, Anna G. Sorace, Enoch Wong, Savitri Krishnamurthy, Anum Syed, Omar Rahal, Thomas E. Yankeelov, Wendy A. Woodward, Marissa Nichole Rylander
In this study, we developed the first three-dimensional, in vitro, vascularized, breast tumor platform to quantify the spatial and temporal dynamics of tumor-vasculature and tumor-ECM interactions specific to IBC.